Factors affecting response to bacillus Calmette-Guérin plus interferon for urothelial carcinoma in situ

Journal of Urology

Volumn 186, Issue 3, 2011, Pages 817-823

  Rosevear, Henry M ^a   Lightfoot, Andrew J ^a   Birusingh, Kevin K ^a   Maymí, José L ^a   Nepple, Kenneth G ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

BCG vaccine; carcinoma in situ; interferons; urinary bladder; urothelium

Indexed keywords

BCG VACCINE; RECOMBINANT ALPHA INTERFERON;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEX DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; AGED; BCG VACCINE; CARCINOMA IN SITU; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RISK FACTORS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 80051544251     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.04.073     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, and E. Ward Cancer statistics, 2009 CA Cancer J Clin 60 2010 5
2. D.G. Skinner, J.P. Richie, and P.H. Cooper The clinical significance of carcinoma in situ of the bladder and its association with overt carcinoma J Urol 112 1974 68
3. D.L. Lamm Carcinoma in situ Urol Clin North Am 19 1992 499
4. M.A. O'Donnell, and A. Boehle Treatment options for BCG failures World J Urol 24 2006 481
5. K.H. Kurth, C. Bouffioux, and R. Sylvester Treatment of superficial bladder tumors: achievements and needs The EORTC Genitourinary Group Eur Urol 37 suppl 2000 1
6. H.W. Herr, C.M. Pinsky, and W.F. Whitmore Jr Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder J Urol 135 1986 265
7. M.D. Melekos, H. Chionis, and A. Pantazakos Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule J Urol 149 1993 744
8. J.W. Davis, S.I. Sheth, and M.J. Doviak Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup J Urol 167 2002 494
9. H.W. Herr, D.M. Schwalb, and Z.F. Zhang Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J Clin Oncol 13 1995 1404
10. R.J. Sylvester, A.P. van der Meijden, and D.L. Lamm Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
11. F. Iori, M. Di Seri, and C. De Nunzio Long-term maintenance bacille Calmette-Guerin therapy in high-grade superficial bladder cancer Urology 59 2002 414
12. A. Ojea, J.L. Nogueira, and E. Solsona A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C Eur Urol 52 2007 1398
13. J.A. Martinez-Pineiro, L. Martinez-Pineiro, and E. Solsona Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial J Urol 174 2005 1242
14. A.S. Belldegrun, J.R. Franklin, and M.A. O'Donnell Superficial bladder cancer: the role of interferon-alpha J Urol 159 1998 1793
15. M.A. O'Donnell, J. Krohn, and W.C. DeWolf Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed J Urol 166 2001 1300
16. L.G. Luciani, E. Neulander, and W.M. Murphy Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach Urology 58 2001 376
17. S.P. Punnen, J.L. Chin, and M.A. Jewett Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy Can J Urol 10 2003 1790
18. P.I. Karakiewicz, S. Benayoun, and D.J. Lewinshtein Treatment of BCG failures with intravesical BCG/interferon: the University of Montreal experience Can J Urol 13 2006 3189
19. F.N. Joudi, B.J. Smith, and M.A. O'Donnell Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urol Oncol 24 2006 344
20. F.N. Joudi, B.J. Smith, and M.A. O'Donnell The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy J Urol 175 2006 1634
21. B.L. Gallagher, F.N. Joudi, and J.L. Maymi Impact of previous bacille Calmette-Guerin failure pattern on subsequent response to bacille Calmette-Guerin plus interferon intravesical therapy Urology 71 2008 297
22. R.S. Weinstein, A.W. Miller 3rd, and B.U. Pauli Carcinoma in situ: comments on the pathobiology of a paradox Urol Clin North Am 7 1980 523
23. E. Solsona, I. Iborra, and R. Dumont The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685
24. R.J. van Gils-Gielen, W.P. Witjes, C.T. Caris Dutch South East Cooperative Urological Group Risk factors in carcinoma in situ of the urinary bladder Urology 45 1995 581
25. H.W. Herr, R.A. Badalament, and D.A. Amato Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression J Urol 141 1989 22
26. P. Gontero, A. Bohle, and P.U. Malmstrom The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer Eur Urol 57 2010 410
27. R.B. Nadler, W.J. Catalona, and M.A. Hudson Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy J Urol 152 1994 367
28. N. Nese, R. Gupta, and M.H. Bui Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis J Natl Compr Canc Netw 7 2009 48
29. K.G. Nepple, A.J. Lightfoot, and H.M. Rosevear Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer J Urol 184 2010 1915
30. R.J. Sylvester, A.P. van derMeijden, and J.A. Witjes Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials J Urol 174 2005 86